New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
10:00 EDTSONS, NAO, FUEL, TTGT, PTCT, MDCA, CLGX, GLNG, CHEF, MOBL, EBMTOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Chef's Warehouse (CHEF) initiated with a Market Perform at BMO Capital... CoreLogic (CLGX) initiated with a Buy at Monness Crespi... Eagle Bancorp (EBMT) initiated with an Outperform at Fig Partners... Golar LNG (GLNG) initiated with a Buy at BofA/Merrill... MDC Partners (MDCA) initiated with an Overweight at Evercore... MobileIron (MOBL) initiated with a Buy at Deutsche Bank... Nordic American Offshore (NAO) initiated with an Overweight at Morgan Stanley... PTC Therapeutics (PTCT) initiated with a Buy at Roth Capital... Rocket Fuel (FUEL) initiated with a Market Perform at Wells Fargo... Sonus Networks (SONS) initiated with an Outperform at Pacific Crest... TechTarget (TTGT) initiated with a Buy at Craig-Hallum.
News For CHEF;CLGX;EBMT;GLNG;MDCA;MOBL;NAO;PTCT;FUEL;SONS;TTGT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 11, 2016
08:31 EDTMOBLArrow Electronics, MobileIron announces North American distribution agreement
Arrow Electronics (ARW) and MobileIron (MOBL) announced a North American distribution agreement that will cover MobileIron's entire product portfolio. This is MobileIron's first comprehensive distribution agreement in North America.
February 10, 2016
16:25 EDTFUELRocket Fuel names Ben Saitz as Chief Customer Officer
Subscribe for More Information
16:14 EDTTTGTTechTarget sees FY16 revenue $120M-$125M, consensus $125.75M
Subscribe for More Information
16:14 EDTTTGTTechTarget sees Q1 revenue $24M-$25M, consensus $25.63M
Sees Q1 adjusted EBITDA $2M-$3M.
16:12 EDTTTGTTechTarget reports Q4 EPS 6c, consensus 12c
Reports Q4 revenue $29.40M, consensus $30.31M.
11:15 EDTNAOWorld's largest shipper says conditions worse than 2008, FT reports
Subscribe for More Information
09:37 EDTGLNGGolar LNG agrees to sell Golar Tundra for $330M
Golar LNG announced that it has entered into a purchase agreement to sell the Golar Tundra, a floating storage and regasification unit, to Golar LNG Partners LP for a sale price of $330M. In connection with the closing, the Partnership will receive a daily fee plus operating expenses, aggregating to approximately $2.6M per month, for Golar's right to use the FSRU from the date of the closing until the date that the Golar Tundra commences operations under its time charter with West Africa Gas Limited. In return, the Partnership will remit to Golar any hire income received with respect to the Golar Tundra during this period. The sale is expected to close in March 2016 and the vessel is expected to commence operations under its time charter with West Africa Gas Limited at the end of the second quarter of 2016.
09:22 EDTGLNGGolar LNG Partners to acquire ownership interest Tundra for $330M
Subscribe for More Information
February 8, 2016
10:17 EDTPTCTSarepta approval seen as 'long shot' as FDA pushes back decision
Shares of drugmaker Sarepta Therapeutics (SRPT) took a dive in morning trading after the company said the U.S. Food and Drug Administration delayed a decision on eteplirsen for the treatment of Duchenne muscular dystrophy. WHAT'S NEW: Sarepta announced that the FDA has pushed out the the Prescription Drug User Fee Act, or PDUFA, date for eteplirsen for the treatment of Duchenne muscular dystrophy to May 26. The previous PDUFA date for the eteplirsen new drug application, or NDA, was originally set for late February. FDA POSTPONEMENT: The FDA notified Sarepta that it's submission of 4-year clinical data, including additional six minute walk test and loss of ambulation data compared to historical control, was designated as a "major amendment" to the NDA and that the PDUFA goal date was extended to allow for a full review of the submission. The FDA previously granted eteplirsen Priority Review status, as well as Rare Pediatric Disease Designation, Orphan Drug Designation and Fast Track Status to eteplirsen. WHAT'S NOTABLE: In late January, the FDA postponed a meeting of its advisory committee to review the Sarepta drug due to an inclement weather forecast for Washington D.C. LONG SHOT: Piper Jaffray analyst Edward Tenthoff told investors in a note that the FDA's PDUFA date postponement for eteplirsen is "not surprising" following the delay of the January 22 AdCom due to weather. Tenthoff also noted that a new AdCom has yet to be scheduled. The analyst continues to see eteplirsen accelerated approval by the new PDUFA date as a "long shot." He believes that the panel discussion will be a "plea from the community" to approve something for DMD and that members will not be asked to vote on drug approval. Tenthoff has a Neutral rating and $15 price target on Sarepta. OTHERS TO WATCH: Other companies developing treatments for Duchenne muscular dystrophy include BioMarin (BMRN) and PTC Therapeutics (PTCT). PRICE ACTION: Sarepta is down 9.5% in morning trading to $11.06.
February 4, 2016
16:27 EDTMOBLMobileIron names Daniel Fields Chief Software Development Officer
Subscribe for More Information
16:25 EDTMOBLMobileIron sees FY16 revenue $160M-$180M, consensus $170.81M
Subscribe for More Information
16:24 EDTMOBLMobileIron sees Q1 revenue $38M-$40M, consensus $39.48M
Subscribe for More Information
16:22 EDTMOBLMobileIron reports Q4 non-GAAP EPS (7c), consensus (13c)
Reports Q4 revenue $43.0M, consensus $41.99M. Q4 gross billings were $48.6M,up 15% year-over-year. Recurring revenue was $26.0M, up 45% year-over-year.
February 3, 2016
07:07 EDTEBMTFIG Partners to hold a forum
Subscribe for More Information
January 29, 2016
11:27 EDTGLNGBarrow, Hanley, Mewhinney & Strauss reports 5.99% passive stake in Golar LNG

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use